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Between March 27, 1989 and December 31, 1997, 1316 
kidney transplantations alone were performed under 
tacrolimus-based immunosuppression at our center. 
Posttransplant lymphoproliferative disorders (PTLD) 
developed in 25 (1.9%) cases; the incidence in adults 
was 1.20/c (1511217). whereas in pediatric patients it 
was 10.IO/c (10/99; P<.OOOl). PTLD was diagnosed 
21.0±22.5 months after transplantation, 25.0±24.7 
months in adults and 14.4±18.2 months in pediatric 
patients. Of the 4 adult cases in whom both the donor 
and recipient Epstein Barr virus (EBV) serologies 
were known, 2 (50%) were seropositive donor -> sero-
negative recipient. Of 7 pediatric cases in whom both 
the donor and recipient EBV serologies were known, 6 
(860/d were EBV seropositive donor -> seronegative 
recipient. Acute rejection was observed before the di-
agnosis ofPTLD in 8 (53%) of 15 adults and 3 (30%) of 10 
pediatric patients. Initial treatment of PTLD included 
a marked decrease or cessation of immunosuppres-
sion with concomitant ganciclovir therapy; two adults 
and two pediatric patients required chemotherapy_ 
With a mean follow-up of 24_9±30.1 months after trans-
plantation. the 1- and 5-year actuarial patient and 
graft survival rates in adults were 930/c and 860/c. and 
80lf( and 60%, respectively. Two adults died, 3.7 and 
46.2 months after transplantation, of complications re-
lated to PTLD, and 10 (including the 2 deaths) lost 
their allograft 3.7-84.7 months after transplantation. 
In children, the 1- and 5-year actuarial patient and 
graft survival rates were 1000/, and 100'7.:, and 100% and 
H90/c, respectively. No child died; one child lost his al-
lograft 41.3 months after transplantation. One child 
had presumed recurrent PTLD that responded to dis-
continuation of tacrolimus and reinitiation of antivi-
ral therapy. The mean serum creatinine level in adults 
was 2.5±1.2 mg/dl. and in children. it was 1.3±0.6 mg/ 
dl. Under tacrolimus-based immunosuppression. 
PTLD is less common after renal transplantation in 
1 Presented In abstract form at the 18th Annual :\leeting of the 
.·,merican Societv ofTranspl:mtation. ~lay 15-19. 1999. Chica"u. IL 
C Thomas E. Starzl Transplantation Institute. 
:l Address correspondence to: Ron Shapiru. :\ID. -lth Floor Falk. 
3601 Fifth Avenue. Pittsbur"h. PA 15213. 
, Di\'isiun of Transplant Pathology. 
-, Di\'ision of Crolof!1c SurgeD'. 
.. Pediatric "'ephrology. 
'. Department of 1\1edicine. 
adults than in children, but PTLD in children is asso-
ciated with more favorable outcomes than in adults. 
Among the many possible complications that can occur 
after renal transplantation, the development of posttrans-
plant lymphoproliferative disorder (PTLD'" I is one of the 
most worrisome. As a manifestation of overimmunosuppres-
sion. it represents an important, if uncommon problem. It 
was first described as a complication of azathioprine-based 
therapy (1-5) and later with cyclosporine-based therapy (6-
8), so that it is not surprising that it has also been seen with 
the new immunosuppressive agents that have become avail-
able over the past several years. Tacrolimus, one of these new 
agents, has been used extensively in our program. It has been 
associated with improved primary and secondary outcomes 
in both adult and pediatric kidney recipients (9-14). How-
ever, particularly in pediatric patients. there has been a 
significant lalthough declining) incidence of PTLD (13, 14). 
Given the relatively large number of patients receiving ta-
crolimus. we thought it would be worthwhile to review the 
incidence of PTLD in our adult and pediatric renal trans-
plant recipients. The purpose of this analysis was to get a 
sense of how common or uncommon a problem PTLD has 
been. and to evaluate the outcomes associated with its occur-
rence. 
PATIENTS AND METHODS 
Between March 27. 1989, and December 3l. 1997. 1316 kidney 
transplantations alone were performed under tacrolimus-based im-
munosuppression at our center. 1217 in adults and 99 in children 
(Table 11. The details of immunosuppressive management with ta-
crolimus-based therap~D have been previously described (.9-141 and 
were not markedly different in the patients who did or did not 
develop PTLD. VeD' few patients 1·5', 1 have received antibod~D 
induction in our program. The numbers of adults and children who 
developed PTLD were taken from an in-house computerized data-
base that has recorded the cases of PTLD on an ongolIlg basis. The 
incidence. recipient age. transplant number. donor status. cold isch-
emia time. mean time to diagnosis. donor and recipient Epstein Barr 
\'irus (EB\' I serololDc status (where known I. and the incidence of 
rejection before the dewlopment of PTLD were tabulated. In addi-
tIOn. the histopathology of the cases of PTLD. their treatment. the 
patient and graft sur;i\'al rates. and the serum creatinine levels in 
the survi\'ing patients with functioning allografts were analyzed . 
, Abbreviations: C:\f\'. c\'tomegalovirus: EBV. Epstein Barr virus: 
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Total 
Adult 
Pediatric 
TABLE 1. Patients and incidence 
Kidney 
transplantation 
1.316 
1.217 
99 
P'I'LD 
25 11.9%1 
15 (1.2'7c) 
10 110.F'cI > P<O.OOI 
3/89-12/92-7/29 124.1'}) > 
V93-12197-3170 14.3%) P<0.003 
RESC'LTS 
Incidence and demographics. There were 25 (1.9%) cases 
of PTLD in the entire group of 1316 patients undergoing 
kidney transplantation (Table 2), Of 1217 adults and 99 
pediatric patients, 15 n.2'7c) and 10 (10.1%), respectively, 
developed PTLD (P<.OOOll. Although the adult incidence 
remained low and relatively constant over time, the pediatric 
incidence declined substantially. Five early (1 year or less 
after transplantation) and 2 late (>3 years) cases of PTLD 
were seen in the first 29 patients \24.1%) who underwent 
transplantation between March 1989 and December 1992, 
and 3 early cases ofPTLD were seen in the 70 patients (4.3%) 
who underwent transplantation between January 1993 and 
December 1997 (P<.003). 
The mean adult recipient age was 46.4:!: 12.7 years (range 
29.2-76.6). Four (26.7%) were undergoing retransplantation, 
none had a panel-reactive antibody over 40%, and 1 (6.7%) 
received a kidney from a living donor la 0 antigen-match 
sister). The mean cold ischemia time (for the cadaveric cases) 
was 31.S:!:S.S hr (range IS.0-50.6) (Table 2). 
The mean pediatric recipient age was 9.0:!:4.5 years (range 
3.1-16.2). One nO%) child was undergoing retransplanta-
tion, none had a panel-reactive antibody over 40%, and 6 
(60%) received kidneys from living donors (4 parents, 1 
grandmother, and 1 adopted father). The mean cold ischemia 
time was 24.S:!:8.6 hr (range 17.2-35.9) (Table 2l. The demo-
graphics of the adults and children who developed or did not 
develop PTLD were generally similar (9-14). 
PTLD was diagnosed 21.0::22.5 months after transplan-
tation, 25.0::24.7 months (range 2.7-78.5) in adults and 
14.4::18.2 months (range 3.6-51.8) in children. In 4 adult 
cases. the donor and recipient EBV serologies were known; :2 
(50%) were seropositive donor - seronegative recipient. In 7 
pediatric cases. 6 (S6%) were seropositive donor -- seroneg-
ative recipient. Biopsy-proven acute rejection was docu-
mented in 8 (53%) of 15 adults and 3 (30%) of 10 children 
before the diagnosis of PTLD. Except where noted above. 
these numbers were too small to allow for meaningful statis-
TABLE 2. Demographics 
Recipient age Iyr) 
Range 
Retransplantation 
Panel-reactive antibody >40% 
Cold ischemia time I hr) 
Living donors 
Time of diagnosis (months after 
transplantation I 
EBV --- Iwhere known) 
Rejection 1 before diagnosis of PTLD) 
.-\dult Pediatric 
46.4::: 12.7 
29.2-76.6 
·l (26.9%) 
o 
31.8::8.8 
116.7%) 
25.0::24.7 
2/4 (50%) 
8/15 (53%) 
9.0::':4.5 
3.1-16.2 
1 110%) 
o 
:24.8::8.6 
6160%) 
14.4::': 18.2 
617 186%) 
3/10 130%) 
----------------- -----
tical comparison. The clinical presentation ofPTLD was vari-
able and ranged from asymptomatic cervical adenopathy to 
vague gastrointestinal complaints to fulminant multisystem 
organ failure. 
Histopathological examination ot' PTLD. Surgical pathol_ 
ogy reports were reviewed. PTLDs were categorized accGrd_ 
ing to the classification recommended by the American Soci-
ety of Hematopathology (15l. Of the 25 patients. 15 had 
monomorphic PTLD, 5 had polymorphic PTLD, and in 2 
cases the tumors had a plasmacytoma-like appearance. In 
the remaining three cases the lesions had features of infec-
tious mononucleosis with areas of polymorphic PTLD. These 
were considered to represent low-grade tumors, which had 
evolved from EBV infection. Two of these low-grade PTLDs 
arose in pediatric patients. and the third was in an adult. Of 
the monomorphic tumors, seven were not further character-
ized due to necrosis, small sample size, or unavailability of 
slides. Five were of a diffuse large B-cell type and three were 
Burkitt-like. 
Eight of the 15 PLTD cases in adults were monomorphic, 4 
were polymorphic, 2 were plasmacytoma-like, and 1 was 
infectious mononucleosis/polymorphic. Seven ofthe 10 PTLD 
cases in children were monomorphic, 1 was polymorphic, and 
2 were infectious mononucleosis/polymorphic. 
The location of the PTLDs was predominantly the gastro-
intestinal tract in 11 cases (44%) or the lymph nodes in 6 
cases (24%). There were also 2 (8%) cases each which pre-
sented in the liver or in the renal allograft, and 1 (4%) case 
each presenting in the lungs, salivary gland. skin, and mul-
tiple organs. 
Treatment of PTLD. After the diagnosis of PTLD, all pa-
tients had either a complete cessation or a marked diminu-
tion of their tacrolimus and steroid dosages, and discontinu-
ation of azathioprine or mycophenolate mofetil, if they were 
taking either of those agents. They were also treated empir-
ically with either intravenous ganciclovir or, less commonly, 
acyclovir \a few pediatric patients also received cytomegalo-
virus [CMV] hyperimmune globulin). :Ylaintenance immuno-
suppression was reintroduced at a low level after the disap-
pearance of the PTLD. In several cases. the patients 
developed rejection before lor even after) immunosuppres-
sion was reintroduced. 
In two adult and two pediatric patients. this conservative 
approach was inadequate. and chemotherapy was required 
(one adult received lymphokine-activated killer cell therapy 
(16). which failed, before starting chemotherapy). In one of 
the adults. chemotherapy was ultimately ineffective. and she 
died ofPTLD; the other adult responded to chemotherapy but 
ultimately lost her kidney 69 months after transplantation. 
to acute rejection. Both of the pediatric patients receiving 
chemotherapy (these were the two late PTLDs occurring 47 
and 52 months after transplantation) had complete eradica-
tion of their PTLD and are back on low-dose immunosuppres-
sion. 
One pediatric patient has had presumed (not biopsy 
proven) recurrent PTLD that was treated successfully with 
ganciclovir and temporary discontinuation of immunosup-
pression. 
Patient and graft survival. With a mean follow-up of 
24.9:!:30.1 months after transplantation. the 1- and 5-year 
actuarial patient survival rates in the adults were 93% and 
86% (Table 3). Two adults died. 3.7 and 46.2 months after 
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TABLE 3. Outcomes 
. -\ctuarial patient survival 
1 year 
.j year 
.-\ctuanal graft survival 
1 year 
.5 vear 
Serum creatinine level I mgJdll 
Adult Pediatnc 
93'l 
86'l 
80('( 
60g 
2.5= 1.2 
1000-
100'l 
lOO''r 
89C7, 
1.3=0.6 
transplantation. of complications related to PTLD (one had 
received chemotherapy. as noted aboveJ. The 1- and 5-year 
actuarial graft survival rates in the adults were 80% and 
60%. In addition to the two deaths. eight adults lost their 
allografts to acute and/or chronic rejection 3.7-84.7 months 
after transplantation (one underwent, before resuming dial-
ysis, retransplantation with a kidney and a pancreas). 
In the pediatric patients with PTLD, the 1- and 5-year 
actuarial patient survival rates were 100% and 100%. No 
child died. The 1- and 5-year actuarial graft survival rates 
were 100% and 89%. One child lost his kidney to chronic 
rejection 41.3 months after transplantation, 36 months after 
the diagnosis of PTLD. 
Renal function. At most recent follow-up. the mean serum 
creatinine level in the five adults with functioning kidneys 
was 2.5:!:1.2 mg/dl; in the nine pediatric patients, it was 
1.3=0.6 mg/dl (Table 3), 
DISCUSSION 
Our experience with PTLD in renal transplant patients 
receiving tacrolimus-based immunosuppression demon-
strated a significantly higher incidence of PTLD in children 
then in adults. This was probably related to a higher propor-
tion of EBV-seropositive donorlEBV-seronegative recipient 
cases in the pediatric patients (6 of the 7 cases in which both 
the donor and recipient EBV serology was knownl. although 
this point is not absolutely certain. given that both donor and 
recipient EBV serologies were known in only '* of the 15 adult 
cases. The incidence of PTLD in the pediatric patients de-
clined significantly over time, from 24.1% in the first 3.5 
years to 4.3% in the subsequent 5 years. The reason for this 
decline probably reflects a conscious effort, beginning in 
1993, to taper tacrolimus and steroid dosages aggressively 
beginning 6-8 weeks after transplantation. with the goal of 
maintaining chronic tacrolimus trough levels of 5-9 ng/ml. 
and discontinuing steroids within 6-12 months after trans-
plantation. In addition. antiviral prophylaxis with ganciclo-
vir and Cl\IV immune globulin began to be used in the high-
risk patients. Although the subsequent decline in the 
incidence of PTLD has been encouraging, it remains too high 
and is the focus of aggressive prophylaxis and monitoring 
r 13.14.17). In EBV-seropositive donorlEBV-seronegative re-
cipient cases. current management includes intravenous and 
oral ganciclovir and CMV immune globulin prophyla..xis 1 IS) 
I the former for up to 1 year and the latter for one or two doses 
in the hospital). and monthly quantitative EBV polymerase 
chain reaction (19) monitoring for the first year after trans-
plantation and every 2-3 months thereafter. A conversion to 
a posItive EBV polymerase chain reaction will prompt rein-
stitution of intravenous ganciclovir and a reduction in immu-
nosuppression. 
Although the incidence of PTLD in children has been rel-
atively high. the outcomes have been generally favorable. 
with 1- and 5-vear actuarial patient survival rates of 100'7c . 
and 1- and R-v~ar actuarial graft survival rates of 100'7c and 
89C"c. respecti~·elyK The mean serum creatinine level has re-
mained reasonable. at 1.3::::0.6 mg/dl. Our overall experience 
with tacrolimus in pediatric renal transplantation has been 
comparable. with 1- and 4-year actuarial patient survival 
rates of 99'7c and 949c. and corresponding 1- and 4-year ac-
tuarial graft survival rates of 989c and 84'7c il41. The ability 
to discontinue steroids and antihypertensive medications in 
669c and 869c of patients. respectively. and the relatively low 
cholesterol levels of 155=31 mg/dl, have been important ad-
ditional advantages for our pediatric patients; many of them 
have had normal growth (4). In contrast. although the inci-
dence of PTLD in adults has been low. the outcomes have 
been less favorable. with 1- and 5-year actuarial patient 
survival rates of 93% and 86%. and 1- and 5-year actuarial 
graft survival rates of 80% and 60%, respectively. In addi-
tion. the mean serum creatinine level of2.5:!:1.2 mg/dl in the 
five patients with functioning allografts reflects somewhat 
impaired function. These outcomes are somewhat worse than 
our overall outcomes in adults (i1, 12,20). 
Our best explanation for these somewhat disparate out-
comes reflects at least partially the fact that most of the 
PTLD cases in children have behaved like EBV infections, 
rapidly disappearing with temporary discontinuation of im-
munosuppression and intravenous ganciclovir. with or with-
out CMV hyperimmune globulin. Many of the adult cases, by 
contrast, were EBV negative and were perhaps less respon-
sive to reduction of immunosuppression and antiviral ther-
apy. 
It should be noted that. although PTLD under tacrolimus-
based therapy represented a significant morbidity for our 
patients and was associated with an increased rate of graft 
loss in our adult patients, it was associated with no mortality 
in our pediatric patients and a 14'1 mortality at 5 years in 
our adult patients. In contrast. single-center reports. registry 
data. and reviews have reported a mortali ty of 50G( or greater 
with PTLD in cyclosporine-treated patients 121. 22, 23). 
In summary, PTLD under tacrolimus-based immunosup-
pression in renal transplant recipients remains an uncom-
mon complication in adults. but. when it occurs, is associated 
with relatively unfavorable outcomes. In pediatric patients, 
the incidence of PTLD has been higher. although it has 
declined significantly over time. and the outcomes have been 
relatively good. These long-term results have been somewhat 
reassuring but have not allowed us to become complacent. 
The goal remains to reduce further or hopefully even elimi-
nate the problem of PTLD in pediatric patients by more 
aggressive prophylaxis and early monitoring. 
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